News

Upcoming Conferences

3rd International Symposium on Scientific and Regulatory Advances in Biological and Non – Biological Complex Drugs: A to Z in Bioequivalence
Budapest, Hungary

» Visit website

NOV, 2018
12-14

News & Press releases

Druggability Technologies USA Announces Appointment of John E. Friend II, M.D. as Chief Medical Officer

New York, Dec 6. 2018 --Druggability technologies USA today announcad that Dr. John E. Friend II has been named as Chief Medical Officer.
Druggability Technologies USA has been engaged by Druggability Technologies Holding (DRGT) to assist with the clinical develeopment of all human trials for DRGT.

» Read more

DRGT wins Best Oral Presentation Award at EUFEPS Annual Meeting 2018

We are proud to announce that DRGT's scientific presentation

"IMPROVED BIOAVAILABILITY OF A NOVEL ABIRATERONE ACETATE FORMULATION IS DRIVEN BY IMMEDIATE TRANSFER OF THE DRUG FROM AMORPHOUS NANOPARTICELS TO BILE MICELLES FOLLOWED BY ITS RAPID CONVERSION TO ABIRATERONE IN THE INTESTINE"

presented by Hristos Glavinas, CSO of DRGT, was selected as Best Oral Presentation at the EUFEPS Annual Meeting 2018.

» See the Award

Best in Class Erectile Dysfunction Drug - DRGT announces dose escalation study results of its Super-Tadalafil DRGT-99

MALTA, May 02, 2018 - DRGT, a specialty pharmaceutical company with a proprietary formulation technology, announced the results of its successful dose escalation PK study for DRGT-99, an innovative formulation of tadalafil. 

» Read more

DRGT announces results of Phase I study expanding clinical utility of the drug Sirolimus utilizing the company's novel Super-API technology platform

MSIDA, Malta, Oct. 05, 2017 - DRGT, a specialty pharmaceutical company, today announced the results of its Phase I study of DRGT18-2, a novel formulation of Sirolimus (Rapamune®), originally a Pfizer product approved by the FDA.

» Read more

DRGT’s novel Celecoxib composition – opportunity for low dose, immediate onset of pain relief with the only NSAID COX-2 inhibitor on the market

19th December 2016, Swatar, Malta - DRGT, a specialty pharmaceutical company announced today the Phase I clinical results of its DRGT-46 and DRGT-47 programs, new compositions of Celecoxib – a COX-2 selective nonsteroidal anti-inflammatory drug (NSAID). 

» Read more

Dr. Philip Kantoff - leading expert in clinical oncology and prostate cancer joins DRGT as Senior Clinical Advisor

14th December 2016, Malta - DRGT, a specialty pharmaceutical company announced today that Dr. Philip Kantoff joined the leadership as Senior Clinical Advisor to accelerate the progress of its ambitious oncology drug development program.

» Read more

DRGT’s novel Abiraterone Acetate composition provides opportunity for dose reduction and increased efficacy in prostate cancer

DRGT announced Phase I clinical results of its DRGT-45 program, a new composition of Abiraterone Acetate - a major drug in the fight against metastatic, castration-resistant prostate cancer.

» Read more

Quotient Clinical begins prostate cancer project for Druggability Technologies

June 23, 2015 - Quotient Clinical, the Translational Pharmaceutics® Company, initiates a new RapidFACT program for Druggability Technologies (DRGT) for evaluating enhanced formulations of abiratone acetate.

» Read more

Druggability Technologies enters into a strategic collaboration with Bayer HealthCare

DRGT signs a broad collaboration agreement with Bayer HealthCare to leverage DRGT’s Super-API Technology to accelerate the discovery and development of novel drugs.

» Read more